Normal function of the cystic fibrosis conductance regulator protein can be associated with homozygous ΔF508 mutation

被引:36
|
作者
Sermet-Gaudelus, I
Vallée, B
Urbin, I
Torossi, T
Marianovski, R
Fajac, A
Feuillet, MN
Bresson, JL
Lenoir, G
Bernaudin, JFO
Edelman, A
机构
[1] Fac Necker, INSERM, U467, F-75015 Paris, France
[2] Hop Necker Enfants Malad, Dept Pediat, F-75015 Paris, France
[3] Hop Necker Enfants Malad, Dept Otorhinolaryngol, F-75015 Paris, France
[4] Univ Paris 06, Lab Histol & Biol Tumorale, Hop Tenon, F-75020 Paris, France
[5] Hop Necker Enfants Malad, Serv Genet, F-75015 Paris, France
[6] Hop Necker Enfants Malad, Ctr Invest Clin, F-75015 Paris, France
关键词
D O I
10.1203/01.PDR.0000032981.64413.AD
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Cystic fibrosis (CF) is caused by mutations of the gene encoding for the CFTR (CF transmembrane conductance regulator) protein. The most frequent mutation, the DeltaF508 mutation, results in a defective cAMP-regulated chloride transport in the epithelial cells. The spectrum of clinical manifestations in patients bearing homozygous DeltaF508 mutations can vary considerably, suggesting that, in the patients with a mild disease, CFFR could be partly functional. To test this hypothesis, we explored in nasal ciliated epithelial cells (NCC) of 9 control subjects and 23 DeltaF508 homozygous patients the anion conductive pathway by a halide sensitive fluorescent dye assay SPQ (6-methoxy-N-3'-sulfopropylquinolinium) and the CFTR transcript levels by RT-PCR. As 50% represented the lowest fraction of the control subjects NCC demonstrating a cAMP-dependent conductance, a CF patient was considered as "cAMP responder" if at least 50% of the NCC tested displayed a cAMP-dependent conductive pathway. According to these criteria, 8 of the 23 patients were considered as cAMP responders. They had a significantly less severe disease considering the respiratory function and infectious status. The amount of CFTR mRNA did not differ between the control subjects and the patients. No statistical correlation could be found between the transcript level and the expression of a cAMP conductive pathway. This cAMP-dependent Cl- conductance detected in homozygous NCC could be due to a residual CFFR activity and may explain the mild phenotypes observed in some DeltaF508 homozygous patients.
引用
收藏
页码:628 / 635
页数:8
相关论文
共 50 条
  • [31] A Delta F508 mutation in mouse cystic fibrosis transmembrane conductance regulator results in a temperature-sensitive processing defect in vivo
    French, PJ
    vanDoorninck, JH
    Peters, RHPC
    Verbeek, E
    Ameen, NA
    Marino, CR
    deJonge, HR
    Bijman, J
    Scholte, BJ
    JOURNAL OF CLINICAL INVESTIGATION, 1996, 98 (06): : 1304 - 1312
  • [32] Interleukin 8 secretion from monocytes of subjects heterozygous or the ΔF508 cystic fibrosis transmembrane conductance regulator gene mutation is altered
    Zaman, MM
    Gelrud, A
    Junaidi, O
    Regan, MM
    Warny, M
    Shea, JC
    Kelly, C
    O'Sullivan, BP
    Freedman, SD
    CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 2004, 11 (05) : 819 - 824
  • [33] Expression of delta F508 cystic fibrosis transmembrane conductance regulator protein and related chloride transport properties in the gallbladder epithelium from cystic fibrosis patients
    Dray-Charier, N
    Paul, A
    Scoazec, JY
    Veissière, D
    Mergey, M
    Capeau, J
    Soubrane, O
    Housset, C
    HEPATOLOGY, 1999, 29 (06) : 1624 - 1634
  • [34] The delta F508 mutation in cystic fibrosis and impact on sinus development
    Woodworth, Bradford A.
    Ahn, Chadwick
    Flume, Patrick A.
    Schlosser, Rodney J.
    AMERICAN JOURNAL OF RHINOLOGY, 2007, 21 (01): : 122 - 127
  • [35] Calnexin Δ185-520 partially reverses the misprocessing of the ΔF508 cystic fibrosis transmembrane conductance regulator
    Okiyoneda, T
    Wada, I
    Jono, H
    Shuto, T
    Yoshitake, K
    Nakano, N
    Nagayama, S
    Harada, K
    Isohama, Y
    Miyata, T
    Kai, H
    FEBS LETTERS, 2002, 526 (1-3) : 87 - 92
  • [36] Neonatal screening for the cystic fibrosis main mutation ΔF508 in Estonia
    Klaassen, T
    Teder, M
    Viikmaa, M
    Metspalu, A
    JOURNAL OF MEDICAL SCREENING, 1998, 5 (01) : 16 - 19
  • [37] A hypothesis regarding the origin and spread of the cystic fibrosis mutation ΔF508
    Dawson, KP
    Frossard, PM
    QJM-MONTHLY JOURNAL OF THE ASSOCIATION OF PHYSICIANS, 2000, 93 (05): : 313 - 315
  • [38] In vivo activation of the cystic fibrosis transmembrane conductance regulator mutant Delta F508 in murine nasal epithelium
    Kelley, TJ
    Thomas, K
    Milgram, LJH
    Drumm, ML
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (06) : 2604 - 2608
  • [39] Evaluation of MRP1-5 gene expression in cystic fibrosis patients homozygous for the ΔF508 mutation
    Hurbain, I
    Sermet-Gaudelus, I
    Vallée, B
    Feuillet, MN
    Lenoir, G
    Bernaudin, JF
    Edelman, A
    Fajac, A
    PEDIATRIC RESEARCH, 2003, 54 (05) : 627 - 634
  • [40] Evaluation of MRP1-5 Gene Expression in Cystic Fibrosis Patients Homozygous for the ΔF508 Mutation
    Ilse Hurbain
    Isabelle Sermet-Gaudelus
    Benoit Vallée
    Marie-Noëlle Feuillet
    Gérard Lenoir
    Jean-François Bernaudin
    Aleksander Edelman
    Anne Fajac
    Pediatric Research, 2003, 54 : 627 - 634